New hair serum shows promise in battle against balding

NCT ID NCT06556056

Completed Disease control Sponsor: NovoBliss Research Pvt Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested a new hair growth serum called SesZen-Bio against a standard treatment (minoxidil 1%) and a placebo in 108 adults with mild to moderate androgenic alopecia (male or female pattern baldness). Participants applied the serum daily to their scalp for several weeks. Researchers measured changes in hair thickness, density, and growth rate using a special imaging device. The goal was to see if the new serum is safe and effective for treating hair loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SesZen-Bio Serum (topical) and Minoxidil 1% serum (topical)
What this could lead to: If it works, this could offer a new topical option for people with mild to moderate hair loss, potentially with fewer side effects than standard treatments.
What could go wrong: This is a small, early-stage study (108 people) with no phase designation. Results may not apply to everyone, and the new serum may not outperform existing options like minoxidil.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENIC ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGENIC ALOPECIA

Contacts and locations

Locations

NovoBliss Research Private Limited

Ahmedabad, Gujarat, 382481, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.